2003: NEOCUTIS, Inc. is founded following years of wound healing research conducted at the prestigious Medical School at the University Hospital of Lausanne, Switzerland.
2005: Discovered through extensive clinical research on wound healing, patented PSP® (Processed Skin Proteins) technology is introduced to offer a solution for anti-aging and post-procedure skincare.
2009: After studying the root cause of skin pigmentation, NEOCUTIS meticulously formulates MELAPLEX® to address the four pathways of pigmentation. This technology offers a Hydroquinone-free skin-brightening alternative to help improve the appearance of skin discoloration in aging skin.
2011: Using the theory that an imbalance in skin’s natural harmony contributes to the appearance of redness, NEOCUTIS crafts ROSAPLEX®, a patent-pending complex designed to help balance skin’s equilibrium.
2013: While anti-oxidant discoveries abound, NEOCUTIS recognized there was still a missing link between a single anti-oxidant and full anti-oxidant protection. On a quest for a truly complete anti-oxidant technology, NEOCUTIS develops VITAPLEX C® to deliver an advanced anti-oxidant defense against environmental stress and skin-aging free radicals.
2013: After a decade of innovation and development of multiple breakthrough skincare technologies, NEOCUTIS is acquired by Merz Pharma Group. This acquisition begins building an expansive complementary aesthetic portfolio for Merz.
2015: As skincare research advanced, a more thorough understanding of the role of the extracellular matrix (ECM) in skin aging emerges. These new insights lead NEOCUTIS to pioneer MPC™ (Micro Protein Complex), an anti-aging technology developed to address all five of the key components in the ECM that impact aging: Collagens I, III, VII, Elastin and Hyaluronic Acid. With MPC™, NEOCUTIS continues to revolutionize anti-aging technology.